HC Wainwright & Co. Reiterates Buy on Pharming, Maintains $37 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Joseph Pantginis has reiterated a Buy rating for Pharming (NASDAQ:PHAR) and maintained a price target of $37.
October 10, 2024 | 4:33 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated its Buy rating for Pharming, maintaining a $37 price target, indicating confidence in the company's future performance.
The reiteration of a Buy rating and maintenance of a $37 price target by a reputable analyst suggests a positive outlook for Pharming, likely boosting investor confidence and potentially driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100